Phosphopeptide enrichment with high selectivity and detection sensitivity is essential for phosphoproteomic studies and remains a long-standing challenge. In this study, new immobilized metal affinity chromatography nanocomposite adsorbents with a phosphonate-functionalized ionic liquid (PFIL) as a surface modifier are successfully prepared via a reaction sequence of amination, quaternization, phosphonate hydrolyzation, and metal immobilization. Taking advantages of integrated features of a flexible and strong tripodal phosphonate chelator, a hydrophilic ionic liquid linker, a large surface area, and the size-exclusion effect, the resulting nanocomposite G@mSiO 2 -PFIL-Ti 4+ exhibits excellent detection sensitivity to enrich phosphorylated peptides from a tryptic β-casein digest (0.15 fmol), and superior enrichment selectivity to capture phosphorylated peptides from a digest mixture of β-casein and bovine serum albumin (a molar ratio of 1:10,000). Strong immobilization of tripodal chelation to metal ions endows the nanocomposite adsorbent with high tolerance to experimental conditions, and thus excellent reusability of the adsorbent has been achieved without remarkable loss of enrichment efficiency for 10 cycles. Due to the excellent size-exclusion effect, high enrichment specificity of G@mSiO 2 -PFIL-Ti 4+ to phosphopeptides has been observed and 23 endogenous phosphopeptides have been captured from human saliva. In addition, 924 phosphopeptides (enrichment specificity, 56.1%) have been identified from the tryptic digest of mouse brain lysate. Particularly, six of 975 phosphorylation sites were Alzheimer's disease-related hyperphosphorylation sites within tau protein. These results demonstrate that G@mSiO 2 -PFIL-Ti 4+ nanocomposite affinity materials show great application potential for a proteomic study of complicated biological samples.

No abstract

No abstract

The characteristics and requirements of a world‐class journal were considered in establishing a rigid peer‐review system for scientific papers submitted for publication in the English‐language Journal of Zhejiang University SCIENCE [JZU(S)] from 2002 onward. Four hundred and thirty‐five contributions were received between January and December 2002, and these were sent for pre‐publication review to appropriate leading scientists in the USA, the UK, Ireland, France, Canada, Australia, Austria, Germany, New Zealand, the Netherlands, Finland, Poland, Portugal, Italy, Israel, Spain, Greece, Belgium, Sweden, Switzerland, Japan, Singapore, Slovakia, India, Greece, the Czech Republic, Mexico, Hong Kong, Macao and Taiwan. Our experience showed that such an international peer‐review system plays an important part in ensuring the high quality of a journal's contents and in helping it achieve an international reputation.

The synergy of multiphoton fluorescence imaging (MP-FI) and magnetic resonance imaging (MRI) provides an imaging platform with high resolution and unlimited penetration depth for early disease detection. Herein, two kinds of terpyridine–Mn­(II) complexes (FD–Mn–O 2 NO and FD–Mn–FD) possessing seven and six coordination modes, respectively, were designed rationally for photodynamic therapy (PDT) guided by MP-FI/MRI. The complexes obtain different multiphoton fluorescence/magnetic resonance properties by adjusting the number of terpyridine ligands. Among them, FD–Mn–FD exhibits the following superiorities: (1) The optimal three-photon excitation wavelength of FD–Mn–FD falls at 1450 nm (NIR-II), which brings high sensitivity and deep tissue penetration in MP-FI. (2) FD–Mn–FD has effective longitudinal relaxation efficiency (r 1 = 2.6 m M–1 s–1), which can be used for T 1-weighted MRI, overcoming the problems of limited tissue penetration depth and low spatial resolution. (3) FD–Mn–FD generates endogenous 1O2 under irradiation by 808 nm light, thereby enhancing the PDT effect in vitro and in vivo. To the best of our knowledge, the complex FD–Mn–FD is the first complex to guide PDT through MP-FI/MRI, providing a blueprint for accurate and effective early detection and timely treatment of the complex in the early stages of cancer.